Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

NCT04869475 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT04869475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04869475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 20, 2021
Completion date
April 30, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory solid tumors